Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GABRP | O00591 | 4/20 | 0.55 |
| ▸ | GABRD | O14764 | 4/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.55 |
| ▸ | GABRE | P78334 | 4/20 | 0.55 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.55 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.55 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.55 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14757636 | 0.83 | NNMT (0.46) | HPGDKDM4EKMT2AGABRPGABRD | |
| SCHEMBL9956934 | 0.83 | SMN1; SMN2 (0.54) | HPGDKDM4EKMT2AGABRPGABRD | |
| SCHEMBL1434641 | 0.81 | HPGD (0.61) | HPGDKDM4EKMT2AGABRPGABRD | |
| SCHEMBL8625804 | 0.81 | GABRP (0.46) | HPGDKDM4EKMT2AGABRPGABRD | |
| SCHEMBL8546294 | 0.79 | HPGD (0.59) | HPGDKDM4EKMT2AGABRPGABRD | |
| SCHEMBL14637332 | 0.79 | KEAP1 (0.46) | HPGDKDM4EKMT2AGABRPGABRD | |
| SCHEMBL991323 | 0.79 | GABRP (0.44) | HPGDKDM4EKMT2AGABRPGABRD | |
| SCHEMBL5320813 | 0.79 | P2RX7 (0.50) | HPGDKDM4EKMT2AHSP90AA1ALDH1A1 | |
| SCHEMBL27910169 | 0.79 | HDAC6 (0.53) | HPGDKDM4EKMT2AGABRPGABRD | |
| SCHEMBL15354443 | 0.79 | JUN (0.45) | HPGDKDM4EKMT2AGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103389373-B | A kind of test paper and application thereof detecting sulfa drugs | Beijing Kwinbon Biotechnology Co.,Ltd. (CN) | 2016-04-20 | — | — | CN | claimed |
| CN-103389373-A | Test paper for detecting sulfonamides, and application thereof | BEIJING KWINBON BIOTECH CO LTD | 2013-11-13 | — | — | CN | claimed |
| US-12617801-B2 | Tetrahydrothieno pyridine derivatives as DDRS inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-05 | — | — | US | disclosed |
| EP-4313994-B1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-05 | — | — | EP | disclosed |
| US-20240199635-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-20 | — | — | US | disclosed |
| EP-4313994-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| CN-117098764-A | Tetrahydrothienopyridine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-110475474-B | Compounds and methods of use | 西格纳姆生物科学公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022200578-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-09-29 | — | — | WO | disclosed |
| US-10947206-B2 | cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-11 | — | — | US | disclosed |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | DAS JAGABANDHU (US) | 2004-02-05 | — | — | US | disclosed |
| US-20030225053-A1 | Compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087085-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-6596746-B1 | protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders; dasatinib | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| CN-1348370-A | Cyclic protein tyrosine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2002-05-08 | — | — | CN | disclosed |
| EP-1169038-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-09 | — | — | EP | disclosed |
| US-6153752-A | Process for preparing heterocycles | CREANOVA, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-2000062778-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617801-B2 | Tetrahydrothieno pyridine derivatives as DDRS inhibitors | DDR1, DDR2, DDRGK1 | HPGD 3350/4885KDM4E 3343/4885KMT2A 3599/4885 |
| US-10947206-B2 | cGAS antagonist compounds | CGAS, STING1, GLS2 | HPGD 771/4885KDM4E 4717/4885KMT2A 4799/4885 |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | HPGD 2229/4885KDM4E 2347/4885KMT2A 2250/4885 |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | TPMT, JAK1, CHUK | HPGD 1177/4885KDM4E 9/4885KMT2A 489/4885 |
| US-20240199635-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | HPGD 2312/4885KDM4E 2650/4885KMT2A 3309/4885 |
| US-20030225053-A1 | Compounds useful in treating cytokine mediated diseases | IL6, IL1A, IL1B | HPGD 326/4885KDM4E 4129/4885KMT2A 4314/4885 |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | LCK, ABL1, BTK | HPGD 2229/4885KDM4E 2347/4885KMT2A 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.